Trodelvy
Payments companies reported to CMS as associated with Trodelvy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Trodelvy, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Trodelvy
These are the largest totals companies reported as associated with Trodelvy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Adam Brufsky | Pittsburgh, PA | $262,357.94 | |
| Devesh Pandya | Houston, TX | Hematology & Oncology | $217,452.54 |
| Wassim Mchayleh | Altamonte Springs, FL | Hematology & Oncology | $209,665.67 |
| Shaina Rozell | Chicago Ridge, IL | Internal Medicine | $202,944.82 |
| Monica Fornier | New York, NY | Medical Oncology | $191,406.55 |
| Victoria Rizk | Basking Ridge, NJ | Hematology & Oncology | $190,107.03 |
| Rena Callahan | Valencia, CA | Internal Medicine | $176,838.09 |
| Ricardo Alvarez | Houston, TX | Medical Oncology | $174,581.78 |
| Anne Odea | Westwood, KS | Medical Oncology | $171,203.89 |
| Andrew Seidman | New York, NY | Medical Oncology | $169,959.52 |
Prescribed Trodelvy?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.